Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Maria Chiara Lazzari(Istituti Ospitalieri di Cremona), Ottavia Bernocchi(University of Trieste), Fabiola Giudici(University of Padua), Giuseppina Barbieri(Istituti Ospitalieri di Cremona), Giovanni Scambia(Agostino Gemelli University Polyclinic), Carlo Azzini(Istituti Ospitalieri di Cremona), Ida Paris(Agostino Gemelli University Polyclinic), Giuseppina Ferrero(Istituti Ospitalieri di Cremona), Gareth Williams(King's College London), Marco Ungari(Istituti Ospitalieri di Cremona), Elisa Zago(University of Verona), Maria Rosa Cappelletti(University of Trieste), Alice Bruson, Valeria Cervoni(University of Trieste), Sergio Aguggini(Istituti Ospitalieri di Cremona), Nicoletta Ziglioli(Istituti Ospitalieri di Cremona), Elena Marasco, Marianna Sirico(Istituti Ospitalieri di Cremona), Davide Cerra, Carla Strina(Istituti Ospitalieri di Cremona), Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Luciano Xumerle, Alfredo Molteni(Istituti Ospitalieri di Cremona), Manuela Milani(Humanitas University), Marco Loddo
Cited by 19
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553